TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04580654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL312
Description: Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa
Study: NCT04094012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazid and rifapentine
Description: This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazid and rifapentine
Description: This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
Study: NCT04370093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Description: 45 mg/day- one pioglitazone tablet once daily throughout the 24 weeks of the study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.

Intervention type: OTHER
Group type: OTHER
Intervention: Pioglitazone + Weight Loss
Description: Pioglitazone + Weight loss following the Group Lifestyle Balance Program based on the Diabetes Prevention Program that utilizes cognitive behavioral strategies (goal setting, problem solving, self-monitoring, stimulus control),and provides written education materials to support health and nutrition behavior changes for weight management and disease prevention.
Study: NCT01866644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Bath transplanted liver with N-acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Bath saline transplanted liver
Study: NCT00357955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral counseling and peer support
Description: Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Education
Description: interactive lectures with hands-on learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Role modeling
Description: learning from peers with similar disease and problems
Study: NCT03624556

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG FontUp
Description: Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FontUp
Description: Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
Study: NCT04497155

Intervention type: DRUG
Intervention: Norepinephrine
Description: Trauma patients with prehospital or arrival to the trauma center hypotension, defined as a systolic blood pressure \<100 mmHg, that received norepinephrine during prehospital transport or in the resuscitation unit.
Study: NCT02757768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride
Description: Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamsulosin Hydrochloride
Description: Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Study: NCT00357955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacologic case management
Description: provided by clinical pharmacists following pre-established algorithms
Study: NCT04480307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temelimab 18 mg/kg
Description: temelimab 18 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temelimab 36 mg/kg
Description: temelimab 36 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temelimab 54 mg/kg
Description: temelimab 54 mg/kg will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given as monthly (4-weekly) intravenous (IV) infusions over 48 weeks (12 administrations in total).
Study: NCT04541706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Lorlatinib will be supplied for oral administration as 25 mg tablets. The recommended dosage of lorlatinib is 100 mg orally once daily.
Study: NCT01996046

Intervention type: OTHER
Intervention: FDG PET/CT scan
Description: \[18F\] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
Study: NCT06675474

Intervention type: OTHER
Intervention: Clinical periodontal measurements
Description: Clinical periodontal measurements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.

Intervention type: OTHER
Intervention: Saliva sampling
Description: The whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 2 minutes, wait for 10 minutes. Then the participants were requested to let the saliva pool in their floor of the mouth and to allow the saliva to drain passively into a falcon tube, 5 minutes.

Intervention type: OTHER
Intervention: Serum Sampling
Description: 5 ml of venous blood were taken from the antecubital vein by a standard venipuncture method.

Intervention type: OTHER
Intervention: GCF sampling
Description: GCF was collected from the six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars, via steril paper strips.

Intervention type: OTHER
Intervention: Subgingival plaque sampling
Description: Subgingival plaque was collected by inserting two standardized paper points (no:30) at six sites (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) per tooth, except the 3rd molars.
Study: NCT01057771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
Study: NCT04060017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoleucovorin Calcium
Description: Liquid leucovorin calcium dosed by weight

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02323620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of BM-MC
Description: Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
Study: NCT06691789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social support
Description: This intervention includes a social support given to the students during COVID-19 pandemic
Study: NCT02562014

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 75g glucose

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 75g glucose

Intervention type: OTHER
Group type: OTHER
Intervention: Inulin
Description: 75g glucose plus 24g inulin

Intervention type: OTHER
Group type: OTHER
Intervention: Inulin
Description: 75g glucose plus 24g inulin

Intervention type: OTHER
Group type: OTHER
Intervention: Resistant Starch
Description: 75g glucose plus 28.2g resistant starch

Intervention type: OTHER
Group type: OTHER
Intervention: Resistant Starch
Description: 75g glucose plus 28.2g resistant starch
Study: NCT04108910

Intervention type: DIAGNOSTIC_TEST
Intervention: Guidance UTI
Study: NCT02561455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: oral tablet
Study: NCT03677024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLN arm
Description: Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
Study: NCT03681340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyapatite toothpaste
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite toothpaste
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoridated toothpaste
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoridated toothpaste
Description: If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
Study: NCT05545462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycyclin
Description: THE USE OF DOXYCYCLIN POWDER IN THE TREATMENT OF UMBILICAL GRANULOMA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMMON SALT
Description: THE USE OF COMMON SALT IN TREATMENT OF UMBILICAL GRANULOMA
Study: NCT03534934

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine Pregnancy Test
Description: Urine pregnancy test done on woman of childbearing potential.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine Pregnancy Test
Description: Urine pregnancy test done on woman of childbearing potential.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: Blood test for vitamin D level, Hemoglobin A1c, and creatinine level

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: Blood test for vitamin D level, Hemoglobin A1c, and creatinine level

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Duel-energy X-ray absorptiometry scan
Description: Bone density measurement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Duel-energy X-ray absorptiometry scan
Description: Bone density measurement

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi-detector computed tomography
Description: Hip and ankle CT scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi-detector computed tomography
Description: Hip and ankle CT scan

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry scan
Description: Vertebral fracture assessment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry scan
Description: Vertebral fracture assessment
Study: NCT01041495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclobenzaprine ER (AMRIX)
Description: active drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo for cyclobenzaprine ER (AMRIX)
Study: NCT01353235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
Study: NCT06690450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venofer® 200 mg
Description: A single 200 mg dose of Venofer® administered by slow intravenous push over 5 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venofer® 100 mg
Description: A single 100 mg dose of Venofer® administered by slow intravenous push over 2 minutes without a test dose.
Study: NCT06690125

Intervention type: DIAGNOSTIC_TEST
Intervention: Classical and computerized assessment
Description: Patients with right hemisphere stroke will undergo a battery of standardized paper-based tests, as part of routine clinical practice, including cognitive assessments.~Additionally, they will complete computerized tests involving the presentation of unisensory (Auditory or Visual Stimuli) and multisensory stimuli (visual and auditory stimuli)

Intervention type: DIAGNOSTIC_TEST
Intervention: Classical and computerized assessment
Description: Patients with right hemisphere stroke will undergo a battery of standardized paper-based tests, as part of routine clinical practice, including cognitive assessments.~Additionally, they will complete computerized tests involving the presentation of unisensory (Auditory or Visual Stimuli) and multisensory stimuli (visual and auditory stimuli)
Study: NCT02946411

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Glucose level will be measured after cardiac surgery.
Study: NCT04279093

Intervention type: OTHER
Intervention: No intervention, but participants will use a smartphone app daily to complete the EPDS
Description: No intervention, but participants will use a smartphone app daily (ClinTouch DAWN-P) to complete the Edinburgh Postnatal Depression Scale
Study: NCT06144658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality Headset / Hololens 2 or Varjo XR3
Description: Augmented Reality Headset
Study: NCT04669197

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel protein bound
Description: combination therapy
Study: NCT01077505

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide 50mg weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive (Brevicon)
Description: Oral contraceptive (Brevicon)
Study: NCT01353235

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: usual care
Description: no drug administered
Study: NCT03206294

Intervention type: OTHER
Group type: OTHER
Intervention: pharmacist assessment
Description: St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
Study: NCT01613118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE-021 (Sparsentan)
Description: Oral, once-daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE-021 (Sparsentan)
Description: Oral, once-daily
Study: NCT04669197

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: combination therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: combination therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine
Description: combination therapy
Study: NCT02902978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E6130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: E6130 matched placebo
Study: NCT02811601

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEAL surgery
Description: Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
Study: NCT04253964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
Study: NCT01613118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE-021 (Sparsentan)
Description: Oral, once-daily
Study: NCT04253964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)
Description: The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13)
Description: The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLQ-C30 Global Health/Quality of Life Questionnaire
Description: 30 item questionnaire - Functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, and nausea and vomiting), global health status and quality of life scale, also several single-item symptom measures
Study: NCT01613118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Oral, once-daily